Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Hjardem, Elisabeth; Østergaard, Mikkel; Pødenphant, Jan; Tarp, Ulrik; Andersen, Lis Smedegaard; Bing, Jèns; Peen, Elisabeth; Lindegaard, Hanne; Ringsdal, Vibeke Stevenius; Rødgaard, Anne; Skøt, Jens; Hansen, Annette; Mogensen, H. H.; Unkerskov, Janne; Hetland, Merete Lund

doi:10.1136/ard.2006.054742

Cited by 95 publications

(64 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There was little information about baseline characteristics; however, it seems that there may be some, if small, differences between studies. The main results of included studies are summarised in 110 Duftner et al 111 and Karlsson et al 112 patients switched TNF inhibitorsowing to lack of efficacy or AEs or for other reasons. The reason for changing from one TNF inhibitor to another was unclear in Solau-Gervais et al 109 Hyrich et al [121][122][123] used data from the BSRBR.…”

Section: Discussionmentioning

confidence: 99%

“…Two studies reported median drug survival. 110,111 Hjardem et al 110 and Duftner et al 111 reported that the median drug survival was 37 weeks and 8.0 months (range 0-43.7 months), respectively.…”

Section: Withdrawalsmentioning

confidence: 99%

“…The inclusion criteria were unclear in two studies. 108,110 It was unclear in most studies whether consecutive patients were included in the study. Nearly one-third (140/477) of patients who met the study inclusion criteria were excluded from Karlsson et al 112 because of dropouts/missing response data at 3 months.…”

Section: Quality Assessmentmentioning

confidence: 99%

“…Four studies were uncontrolled and retrospective. [110][111][112][113] Finckh et al 136,138 was a non-randomised comparative study (TNF inhibitors vs RTX). This section presents data only for TNF inhibitors.…”

Section: Quality Assessmentmentioning

confidence: 99%

See 3 more Smart Citations

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAAdalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation Dr Paresh Jobanputra has participated in several technology assessments/appraisals related to rheumatoid arthritis as the clinical expert of the assessment group. He works as consultant rheumatologist in a large department of rheumatology. His department has taken part in clinical trials of etanercept, adalimumab, rituximab and tocilizumab. The department receives funding for nurses from Schering-Plough Ltd to administer infliximab to patients currently being treated with this drug. Currently he is the chief investigator of a clinical trial comparing adalimumab versus etanercept (ISRCTN95861172). He has, in the past, received support for educational purposes from Wyeth Pharmaceuticals (etanercept), Abbott (adalimumab) and Roche (rituximab). He has also been involved in an advisory board for Roche in relation to tocilizumab and rituximab, and has accept...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Withdrawalsmentioning

confidence: 99%

Section: Quality Assessmentmentioning

confidence: 99%

Section: Quality Assessmentmentioning

confidence: 99%

See 2 more Smart Citations

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Malottki

Barton²,

Tsourapas³

et al. 2011

Health Technol Assess

229

150

View full text Add to dashboard Cite

show abstract

“…[84][85][86] An analysis of the Danish Database for Biological Therapies in Rheumatology (DANBIO) showed that patients with RA benefit from the switching of anti-TNF drugs. [87] Active RA patients refractory to DMARD or TNF blockers were included in a rituximab meta-analysis, and ACR 20, 50, and 70 responses were evaluated. Rituximab and MTX combination treatment was found to be effective and associated with low adverse effect incidence in refractory cases.…”

Section: Depending On the Clinical Characteristics In Dmard-naive Patmentioning

confidence: 99%

Management of Rheumatoid Arthritis: Consensus Recommendations From the Turkish League Against Rheumatism

Ataman

2011

Turk J Rheumatol

View full text Add to dashboard Cite

Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort

Zhang

Shan

Reed

et al. 2011

Arthritis Care & Research

View full text Add to dashboard Cite

Objective The study aims to examine the threshold in disease activity associated with switching biologic treatment regimens in RA patients in real-world clinical practice. Methods Using data from a prospective observational North American cohort of RA patients through 12/30/2009, patients who initiated a new anti-TNF agent with ≥ 6 months of follow-up were identified. Patients were classified as switchers or maintainers depending on whether they continued their anti-TNF treatment or switched (including discontinuation) within 12 months. Level of disease activity measured by CDAI and DAS28 at time of switch (corresponding follow-up visit for maintainers) was examined and random effect multivariable logistic regression was used to adjust for covariates. Results Mean age and RA duration among 1,549 eligible patients were 56.1 and 9.6 years, 80% were women, 62% were initiating their 1st biologic and 30% 2nd. At time of switch, the median DAS28 and CDAI were 3.1 and 8.4 among maintainers, and 4.0 and 15.2 among switchers. Maintainers also experienced a greater amount of reduction in disease activity compared with switchers (CDAI: −7.7 vs. −2.3; DAS28: −1.1 vs. −0.3). The threshold to switch decreased over calendar time, with the greatest amount of reduction observed among patients with moderate disease activity. Conclusion On average, physicians and patients were willing to continue biologic treatment for patients who are at or near low disease activity. The threshold to switch decreased over time, especially among partial responders.

show abstract

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Cited by 95 publications

References 15 publications

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation

Management of Rheumatoid Arthritis: Consensus Recommendations From the Turkish League Against Rheumatism

Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort

Contact Info

Product

Resources

About